EP4720675A2 - Menschliche monoklonale antikörper gegen menschliches parainfluenzavirus typ 3 - Google Patents

Menschliche monoklonale antikörper gegen menschliches parainfluenzavirus typ 3

Info

Publication number
EP4720675A2
EP4720675A2 EP24816110.1A EP24816110A EP4720675A2 EP 4720675 A2 EP4720675 A2 EP 4720675A2 EP 24816110 A EP24816110 A EP 24816110A EP 4720675 A2 EP4720675 A2 EP 4720675A2
Authority
EP
European Patent Office
Prior art keywords
antibody
fragment
sequences
clone
paired
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24816110.1A
Other languages
English (en)
French (fr)
Inventor
James E. Crowe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of EP4720675A2 publication Critical patent/EP4720675A2/de
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP24816110.1A 2023-05-26 2024-05-08 Menschliche monoklonale antikörper gegen menschliches parainfluenzavirus typ 3 Pending EP4720675A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363504549P 2023-05-26 2023-05-26
PCT/US2024/028239 WO2024249042A2 (en) 2023-05-26 2024-05-08 Human monoclonal antibodies for human parainfluenza virus type 3

Publications (1)

Publication Number Publication Date
EP4720675A2 true EP4720675A2 (de) 2026-04-08

Family

ID=93658796

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24816110.1A Pending EP4720675A2 (de) 2023-05-26 2024-05-08 Menschliche monoklonale antikörper gegen menschliches parainfluenzavirus typ 3

Country Status (2)

Country Link
EP (1) EP4720675A2 (de)
WO (1) WO2024249042A2 (de)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201019959A (en) * 2008-08-19 2010-06-01 Regeneron Pharma Human antibodies to human RANKL
SMT202000091T1 (it) * 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
WO2021222827A1 (en) * 2020-05-01 2021-11-04 Meso Scale Technologies, Llc. Methods and kits for virus detection
TW202227481A (zh) * 2020-11-04 2022-07-16 美國洛克菲勒大學 中和抗sars-cov-2抗體
WO2023091609A2 (en) * 2021-11-18 2023-05-25 Twist Bioscience Corporation Cytokine variant antibodies and methods of use

Also Published As

Publication number Publication date
WO2024249042A3 (en) 2025-06-05
WO2024249042A2 (en) 2024-12-05

Similar Documents

Publication Publication Date Title
EP4045533B1 (de) Menschliche monoklonale antikörper gegen das schwere akute atemwegssyndrom coronavirus 2 (sars-cov-2)
US12410241B2 (en) Human monoclonal antibodies to enterovirus D68
US20210277092A1 (en) HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
WO2021195326A1 (en) Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
US20230122364A1 (en) HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
US20230073075A1 (en) Human hendra virus and nipah virus antibodies and methods of use therefor
US12233127B2 (en) Human monoclonal antibodies to a new universal influenza A hemagglutinin head domain epitope
US12534512B2 (en) Human monoclonal antibodies to hantavirus and methods of use therefore
WO2021195385A1 (en) HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
US20230063625A1 (en) Human antibodies to rift valley fever virus
WO2024173657A2 (en) Antibodies to human pneumoviruses and methods of use therefor
US20230181714A1 (en) Human monoclonal antibodies to venezuelan equine encephalitis virus and uses therefor
US11939370B2 (en) Pan-ebola virus neutralizing human antibodies and methods of use therefor
WO2024249042A2 (en) Human monoclonal antibodies for human parainfluenza virus type 3
US20250304659A1 (en) HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 1 (SARS-CoV-1)
US20250277015A1 (en) Human monoclonal antibodies to eastern equine encephalitis virus and uses therefor
WO2025024431A1 (en) Broadly reactive antibodies to influenza b viruses
WO2026036058A1 (en) Human antibodies to crimean congo hemorrhagic fever virus
WO2024015760A2 (en) Human monoclonal antibodies to omicron variant of severe acute respiratory syndrome coronavirus 2 (sars-cov- 2)
US20240288426A1 (en) Human antibodies to crimean congo hemorrhagic fever virus
US20230085393A1 (en) Human antibodies that neutralize zika virus and methods of use therefor
WO2023187407A1 (en) Human monoclonal antibodies binding to sars-cov-2 and methods of use thereof
HK40113917A (en) Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
WO2022132710A1 (en) Human hendra virus and nipah virus antibodies and methods of use therefor
HK40080049B (en) Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251203

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR